Mette Deleuran

European Guideline (<scp>EuroGuiDerm</scp>) on atopic eczema: Living update

Long‐term socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis

Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)

Italian S3-Guideline on the treatment of Atopic Eczema - Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

Italian S3-Guideline on the treatment of Atopic Eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study

First update of the living European guideline (<scp>EuroGuiDerm</scp>) on atopic eczema

Systemic anti‐inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe

Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in <scp>patient‐reported</scp> symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

European guideline (<scp>EuroGuiDerm</scp>) on atopic eczema – part <scp>II</scp>: non‐systemic treatments and treatment recommendations for special <scp>AE</scp> patient populations

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies

European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics

Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

Association Between Atopic Dermatitis and Educational Attainment in Denmark

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis

The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate‐to‐severe atopic eczema*

European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis

How “benign” is cutaneous mastocytosis? A Danish registry-based matched cohort study

The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion

<scp>TRE</scp> atment of <scp>AT</scp> opic eczema ( <scp>TREAT</scp> ) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema